101 related articles for article (PubMed ID: 23060390)
1. Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review.
Zhang X; Yang XR; Huang XW; Wang WM; Shi RY; Xu Y; Wang Z; Qiu SJ; Fan J; Zhou J
Hepatobiliary Pancreat Dis Int; 2012 Oct; 11(5):458-66. PubMed ID: 23060390
[TBL] [Abstract][Full Text] [Related]
2. Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma.
Lee JE; Bae SH; Choi JY; Yoon SK; You YK; Lee MA
World J Gastroenterol; 2014 Jan; 20(1):235-41. PubMed ID: 24415877
[TBL] [Abstract][Full Text] [Related]
3. Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis.
Wang P; Tan G; Zhu M; Li W; Zhai B; Sun X
Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):1-8. PubMed ID: 28847184
[TBL] [Abstract][Full Text] [Related]
4. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.
Vincenzi B; Santini D; Russo A; Addeo R; Giuliani F; Montella L; Rizzo S; Venditti O; Frezza AM; Caraglia M; Colucci G; Del Prete S; Tonini G
Oncologist; 2010; 15(1):85-92. PubMed ID: 20051477
[TBL] [Abstract][Full Text] [Related]
5. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.
Sonbol MB; Riaz IB; Naqvi SAA; Almquist DR; Mina S; Almasri J; Shah S; Almader-Douglas D; Uson Junior PLS; Mahipal A; Ma WW; Jin Z; Mody K; Starr J; Borad MJ; Ahn DH; Murad MH; Bekaii-Saab T
JAMA Oncol; 2020 Dec; 6(12):e204930. PubMed ID: 33090186
[TBL] [Abstract][Full Text] [Related]
6. The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma.
Cabrera R; Limaye AR; Horne P; Mills R; Soldevila-Pico C; Clark V; Morelli G; Firpi R; Nelson DR
Aliment Pharmacol Ther; 2013 Jan; 37(1):91-7. PubMed ID: 23094860
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma.
Marta GN; da Fonseca LG; Braghiroli MI; Moura F; Hoff PM; Sabbaga J
Clinics (Sao Paulo); 2021; 76():e2498. PubMed ID: 33503195
[TBL] [Abstract][Full Text] [Related]
8. Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma.
Kelley RK; Meyer T; Rimassa L; Merle P; Park JW; Yau T; Chan SL; Blanc JF; Tam VC; Tran A; Dadduzio V; Markby DW; Kaldate R; Cheng AL; El-Khoueiry AB; Abou-Alfa GK
Clin Cancer Res; 2020 Sep; 26(18):4795-4804. PubMed ID: 32636319
[TBL] [Abstract][Full Text] [Related]
9. [Effect of ozone oil for prevention and treatment of sorafenib-induced hand-foot skin reactions: a randomized controlled trial].
Chen X; Jiang Y; Zhang Y; Dai W; Fan R; Weng X; He P; Yan F; Guo Y
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Oct; 40(10):1488-1492. PubMed ID: 33118519
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of sorafenib in older adults with advanced hepatocellular carcinoma: An analysis of a majority Hispanic cohort.
Arora SP; Ananth S; Ketchum N; Gelfond J; Michalek J; Mahalingam D
J Geriatr Oncol; 2020 Sep; 11(7):1157-1160. PubMed ID: 32273248
[No Abstract] [Full Text] [Related]
11. Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis.
Rizzo A; Ricci AD; Fanizzi A; Massafra R; De Luca R; Brandi G
Curr Oncol; 2023 Jan; 30(1):749-757. PubMed ID: 36661706
[TBL] [Abstract][Full Text] [Related]
12. Is the Concurrent Use of Sorafenib and External Radiotherapy Feasible for Advanced Hepatocellular Carcinoma? A Meta-Analysis.
Rim CH; Park S; Shin IS; Yoon WS
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34200809
[TBL] [Abstract][Full Text] [Related]
13. Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review.
Kim JH; Kim BJ; Jang HJ; Lee J
Oncotarget; 2017 Nov; 8(60):102321-102327. PubMed ID: 29254247
[TBL] [Abstract][Full Text] [Related]
14. Tumor burden affects the progression pattern on the prognosis in patients treated with sorafenib.
Sun J; Xia D; Bai W; Li X; Wang E; Yin Z; Han G
Front Oncol; 2024; 14():1405178. PubMed ID: 38715786
[TBL] [Abstract][Full Text] [Related]
15. Retraction Note: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
Oya M; Kaneko S; Imai T; Tsujino T; Sunaya T; Okayama Y
Cancer Chemother Pharmacol; 2024 May; 93(5):523. PubMed ID: 37715787
[No Abstract] [Full Text] [Related]
16. A systematic review of sorafenib in Child-Pugh A patients with unresectable hepatocellular carcinoma.
Shen A; Tang C; Wang Y; Chen Y; Yan X; Zhang C; Liu R; Wei X; Zhu Y; Zhang H; Wu Z
J Clin Gastroenterol; 2013; 47(10):871-80. PubMed ID: 24100749
[TBL] [Abstract][Full Text] [Related]
17. Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma.
Zhang X; Yang XR; Sun C; Hu B; Sun YF; Huang XW; Wang Z; He YF; Zeng HY; Qiu SJ; Cao Y; Fan J; Zhou J
Cancer Lett; 2015 Sep; 366(1):112-22. PubMed ID: 26118777
[TBL] [Abstract][Full Text] [Related]
18. Plasma microRNA, a potential biomarker for acute rejection after liver transplantation.
Hu J; Wang Z; Tan CJ; Liao BY; Zhang X; Xu M; Dai Z; Qiu SJ; Huang XW; Sun J; Sun QM; He YF; Song K; Pan Q; Wu Y; Fan J; Zhou J
Transplantation; 2013 Apr; 95(8):991-9. PubMed ID: 23466638
[TBL] [Abstract][Full Text] [Related]
19. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling.
Zhou SL; Zhou ZJ; Hu ZQ; Li X; Huang XW; Wang Z; Fan J; Dai Z; Zhou J
Cancer Lett; 2015 Mar; 358(2):124-135. PubMed ID: 25462858
[TBL] [Abstract][Full Text] [Related]
20. Expression of hemopexin in acute rejection of rat liver allograft identified by serum proteomic analysis.
Xu M; Tan C; Hu J; Alwahsh SM; Yan J; Hu J; Dai Z; Wang Z; Zhou J; Fan J; Huang X
Shock; 2014 Jul; 42(1):65-74. PubMed ID: 24667618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
